Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 4:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Early Highly Effective Therapies Group Clear all
Completed Phase 3 Interventional Results available

Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure

NCT00894387
View directory record Official record
Conditions
Acute Decompensated Heart Failure, Congestive Heart Failure
Interventions
Aliskiren, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
37
States / cities
Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Sep 28, 2026, 4:00 PM EDT
Completed No phase listed Observational

Ultrasonic Perfusion Estimation in Calf Muscle

NCT04755335
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Ultrasound
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Sep 28, 2026, 4:00 PM EDT
Completed Phase 2 Interventional Results available

Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer

NCT05498155
View directory record Official record
Conditions
Breast Cancer
Interventions
Neoadjuvant Olaparib monotherapy group, Neoadjuvant combination therapy with olaparib plus durvalumab
Drug · Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Loveland, Colorado • Boston, Massachusetts • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 28, 2026, 4:00 PM EDT
Active, not recruiting Not applicable Interventional

Interventions for English Language Learners At-Risk for ADHD

NCT05918991
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Daily Report Card, Language Intervention
Behavioral · Other
Lead sponsor
Florida International University
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 28, 2026, 4:00 PM EDT
Recruiting Phase 4 Interventional

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

NCT07225361
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
Interventions
Ublituximab
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 28, 2026, 4:00 PM EDT
Terminated Phase 2 Interventional

A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease

NCT04619420
View directory record Official record
Conditions
Alzheimer Disease, Cognitive Dysfunction, Dementia
Interventions
JNJ-63733657, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
55 Years to 80 Years
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
55
States / cities
Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 47 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 28, 2026, 4:00 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease

NCT03352557
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
BIIB092, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 80 Years
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 28, 2026, 4:00 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease

NCT03100149
View directory record Official record
Conditions
Parkinson's Disease
Interventions
RO7046015, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 80 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2031
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 28, 2026, 4:00 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

NCT07636811
View directory record Official record
Conditions
Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Interventions
Mivelsiran, Placebo
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
40 Years to 55 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Maitland, Florida • Naples, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 28, 2026, 4:00 PM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Sep 28, 2026, 4:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Implementation and Biobehavioral Study of Temporomandibular Joint and Muscle Disorder (TMJMD)

NCT00952900
View directory record Official record
Conditions
Temporomandibular Joint and Muscle Disorder
Interventions
Biobehavioral, Active Coping/Attention Intervention
Behavioral
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Jun 7, 2015 · Synced Sep 28, 2026, 4:00 PM EDT
Not listed Not applicable Interventional

Using Web-based Technology to Expand and Enhance Applied Behavioral Analysis Programs for Children With Autism in Military Families

NCT01614275
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Technology-Enhanced Parent Training, Technology-Enhanced Tutor Training, Technology-enhanced Early Intensive Behavioral Intervention, No-Intervention
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
18 Months to 48 Months
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Sep 28, 2026, 4:00 PM EDT
Completed Not applicable Interventional Results available

Lymphedema Prophylaxis in Breast Cancer Survivors Who Show Early Evidence of High-risk Status

NCT00383500
View directory record Official record
Conditions
Lymphedema, Breast Cancer
Interventions
Flexitouch, Class 1 compression garment
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Sep 28, 2026, 4:00 PM EDT
Completed Not applicable Interventional

Cognitive-Based Compassion Training (CBCT) for People Living With HIV (PLHIV)

NCT02395289
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Cognitive-Based Compassion Training (CBCT), Health discussion
Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 28, 2026, 4:00 PM EDT
Active, not recruiting Phase 4 Interventional

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

NCT03535298
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Early Highly Effective Therapies Group, Escalation Therapies Group
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
15
States / cities
Aurora, Colorado • Minneapolis, Minnesota • Rochester, Minnesota + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 28, 2026, 4:00 PM EDT
Completed Not applicable Interventional

Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled Expansion Stents

NCT04315571
View directory record Official record
Conditions
Hypertension, Portal, Ascites
Interventions
Gore® Viatorr® Endoprosthesis with controlled expansion, Large Volume Paracentesis with albumin infusion
Device · Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 28, 2026, 4:00 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Early FMT for C.Difficile

NCT02465463
View directory record Official record
Conditions
Clostridium Difficile
Interventions
Fecal microbiota transplant (FMT), flexible sigmoidoscopy
Procedure · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 79 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Sep 28, 2026, 4:00 PM EDT
Recruiting Phase 3 Interventional

Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

NCT07068074
View directory record Official record
Conditions
Cutaneous Melanoma
Interventions
Adjuvant Therapy, Comprehensive Geriatric Assessment, Computed Tomography, Positron Emission Tomography, Questionnaire Administration, Sentinel Lymph Node Biopsy, Surveillance, Ultrasound Imaging, Wide Local Excision
Procedure · Other · Behavioral
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
75 Years and older
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
181
States / cities
Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 28, 2026, 4:00 PM EDT